Adaptimmune has become one of the first firms to have a drug accepted into EMA’s PRIME regulatory fast-track initiative.

Pfizer has secured an exclusive option to acquire Western Oncolytics’ WO-12 once the oncolytic vaccinia virus has completed Phase I.

Celgene highlighted a handful of immuno-oncology deals that are driving its long-term R&D prospects including Juno and bluebird CAR-T partnerships.

Gene editing biotech Editas Medicine has signed a three-year R&D collab deal with Milan-based San Raffaele Telethon Institute for Gene Therapy to develop…

Regulus Therapeutics saw its shares nosedive last month when the FDA put a clinical trial hold on its leading hep C candidate RG-101--but the company said this…

AstraZeneca has dropped 6 drug programs from its pipeline--with almost all the early-stage candidates being axed from its MedImmune biologics arms--in what is…

Genmab and J&J bag a breakthrough designation, Merck dumps ALK, uniQure yo-yos on gene therapy data and more.

Shares in uniQure briefly hit a new low following a negative knee-jerk reaction to fresh data on its hemophilia B gene therapy.